Altria Rises 13% YTD: Should You Buy, Sell or Hold the Stock?

Altria Group, Inc. MO has delivered solid year-to-date gains as its strategic focus on smoke-free products, disciplined pricing and portfolio management continues to support earnings despite persistent declines in cigarette volumes. The stock has risen 12.8% year to date (“YTD”), slightly outperforming the S&P 500’s 12.7% gain and exceeding the 6.7% increase in the Zacks Consumer Staples sector. The Zacks Tobacco industry has advanced 10.2% during the same period.

Performance among MO’s peers, Philip Morris International Inc. PM, Turning Point Brands, Inc. TPB and British American Tobacco p.l.c. BTI, has been mixed. Philip Morris has gained 17.8%, outperforming MO, while British American Tobacco has risen 1.3%. Meanwhile, Turning Point Brands has declined 20.4%, highlighting the varied performance across the tobacco space.

MO Price Performance 

Image Source: Zacks Investment Research

As of the latest trading session, Altria closed at $65.08, about 15.5% below its 52-week high of $77.06 reached on July 28, 2026. The company continues to capitalize on opportunities in the smoke-free product segment while strengthening its traditional tobacco business, supporting earnings resilience and shareholder returns.

Altria’s Winning Strategies

Altria continues to demonstrate earnings resilience through disciplined pricing and strong execution. In the second quarter of 2026, adjusted EPS increased 2.8% year over year to $1.48, while first-half adjusted EPS rose 4.9% to $2.80. Smokeable products remained a key earnings contributor, with higher pricing helping offset lower shipment volumes and increased promotional investments. This ability to protect profitability amid volume pressure remains an important strength. 

Altria is also strengthening its smoke-free portfolio, with on! PLUS showing encouraging early traction in nicotine pouches, supported by sequential and year-over-year retail-share gains. In the second quarter, Helix expanded on! PLUS to 120,000 stores nationwide and resumed shipments of the 12-milligram product in select states. The company plans a broader national expansion, along with new flavors across multiple nicotine strengths. Management believes these initiatives can broaden on!’s consumer appeal and strengthen its position in the nicotine pouch category.

At the same time, Altria is using a data-driven, total-portfolio approach to strengthen its traditional tobacco business. Marlboro Cowboy Cut generated strong interest among premium smokers, while Basic continued to gain traction in the discount segment during the second quarter. The strategy allows Altria to address different consumer preferences while using pricing and portfolio management to support smokeable products’ profitability despite declining cigarette volumes.

Altria’s Valuation Picture

Altria is currently trading at an attractive valuation compared with the broader industry. The stock's forward 12-month P/E ratio stands at 11.24, well below the industry average of 15.00, highlighting its appeal as a value opportunity. By comparison, peers such as Philip Morris and Turning Point Brands trade at much higher multiples of 21.35 and 35.20, respectively, while British American Tobacco trades at 11.35.

MO P/E Ratio (Forward 12 Months)

Image Source: Zacks Investment Research

What Could Weigh on MO’s Growth?

Altria continues to face pressure from declining cigarette volumes, which remains a key challenge for its traditional tobacco business. In the second quarter of 2026, domestic cigarette shipment volume declined 3.2% year over year, while inventory-adjusted volume fell an estimated 4.5%. Higher pricing helped offset some of the volume weakness, but increased promotional investments and a greater mix of discount shipments also weighed on performance. 

The oral tobacco business is another area of concern. Second-quarter net revenues in the segment declined 5.3%, while adjusted OCI fell 8%. Shipment volume decreased 8.5% due to retail share losses and trade inventory movements, partially offset by industry growth. This weakness highlights the challenge of transitioning the portfolio toward smoke-free products while maintaining profitability across the broader oral tobacco business.

Altria Witnessing Downward Estimate Revision

Reflecting cautious sentiment around Altria, the Zacks Consensus Estimate for EPS has seen downward revisions. Over the past seven days, the EPS estimate for 2026 declined a penny to $5.67, while the 2027 estimate fell 2 cents to $5.84.

Image Source: Zacks Investment Research

Here’s How to Play MO Stock

Altria’s solid YTD performance reflects the strength of its smoke-free strategy, pricing power and disciplined portfolio management. The company continues to expand on! PLUS while protecting profitability in its traditional tobacco business. However, persistent cigarette volume declines and weakness in oral tobacco remain key challenges. Its attractive valuation provides some support, but the mixed operating trends warrant a balanced approach. Currently, the stock appears better suited for holding rather than aggressive buying and carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research